Dr. Reddy’s, Senores launch Ketorolac Tromethamine Tablets in US
Dr. Reddy’s Laboratories and its partner Senores Pharmaceuticals have launched Ketorolac Tromethamine Tablets USP, 10 mg, in the US market.
The launched product is a generic equivalent of Toradol Tablets, 10 mg, which has the approval of the US Food and Drug Administration (FDA) for the short-term treatment of moderate to severe pain in adults.
Ketorolac Tromethamine Tablets USP, 10 mg, is a nonsteroidal anti-inflammatory drug (NSAID). It can be used for up to five days in adults for managing pain that needs analgesia at the opioid level and only as continuation treatment after intravenous or intramuscular dosing of ketorolac tromethamine, if required.
Marc Kikuchi — CEO of Dr. Reddy’s Laboratories North America Generics said: “We are excited about this launch, and pleased to partner with Senores to create affordable access to this product and expand our portfolio in the US market.”
According to IQVIA, the Toradol Tablets, 10 mg brand and generic had sales of around $16.8 million MAT in the US for the most recent 12 months ending in March 2022.
Swapnil Shah – Managing Director of Senores Group said: “Our constant dedication has contributed to expanding our product portfolio, and today we are a significant and reliable supplier of this product.”
Dr. Reddy’s Laboratories said that Ketorolac Tromethamine Tablets USP, 10 mg, are available in bottle count sizes of 100.